
Opinion|Videos|March 12, 2024
Efficacy and Safety and Emerging Combinations
Author(s)Robert J. Motzer, MD
Dr. Motzer provides his perspective on emerging efficacy and safety data updates from KEYNOTE-B61, and Nivolumab+Cabozantinib, evaluating combination regimens in nccRCC.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
NCCN Updates Breast Cancer Guidelines: Sacituzumab Govitecan for 1L TNBC
2
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
3
FDA Grants FTD to GPRC5D Bispecific LBL-034 for R/R Multiple Myeloma
4
Multiomic Real-World Data Predict Outcomes in Metastatic Breast Cancer
5



















